Literature DB >> 24055000

Cardiac matrix: a clue for future therapy.

Paras Kumar Mishra1, Srikanth Givvimani, Vishalakshi Chavali, Suresh C Tyagi.   

Abstract

Cardiac muscle is unique because it contracts ceaselessly throughout the life and is highly resistant to fatigue. The marvelous nature of the cardiac muscle is attributed to its matrix that maintains structural and functional integrity and provides ambient micro-environment required for mechanical, cellular and molecular activities in the heart. Cardiac matrix dictates the endothelium myocyte (EM) coupling and contractility of cardiomyocytes. The matrix metalloproteinases (MMPs) and their tissue inhibitor of metalloproteinases (TIMPs) regulate matrix degradation that determines cardiac fibrosis and myocardial performance. We have shown that MMP-9 regulates differential expression of micro RNAs (miRNAs), calcium cycling and contractility of cardiomyocytes. The differential expression of miRNAs is associated with angiogenesis, hypertrophy and fibrosis in the heart. MMP-9, which is involved in the degradation of cardiac matrix and induction of fibrosis, is also implicated in inhibition of survival and differentiation of cardiac stem cells (CSC). Cardiac matrix is distinct because it renders mechanical properties and provides a framework essential for differentiation of cardiac progenitor cells (CPC) into specific lineage. Cardiac matrix regulates myocyte contractility by EM coupling and calcium transients and also directs miRNAs required for precise regulation of continuous and synchronized beating of cardiomyocytes that is indispensible for survival. Alteration in the matrix homeostasis due to induction of MMPs, altered expression of specific miRNAs or impaired signaling for contractility of cardiomyocytes leads to catastrophic effects. This review describes the mechanisms by which cardiac matrix regulates myocardial performance and suggests future directions for the development of treatment strategies in cardiovascular diseases.
© 2013.

Entities:  

Keywords:  APT; Angiogenesis; CPC; CSC; CVD; DNA methyl transferase; DNMT; ECM; Heart; MMP; MicroRNA; ROS; SERCA; Stem cell; TIMP; VEGF; acute pulmonary thromboembolism; cardiac progenitor cell; cardiac stem cell; cardiovascular disease; extracellular matrix; matrix metalloproteinase; miRNA; reactive oxygen species; sarco endoplasmic reticulum ca(2+)ATPase; tissue inhibitor of MMP; vascular endothelial growth factor

Mesh:

Substances:

Year:  2013        PMID: 24055000      PMCID: PMC4111554          DOI: 10.1016/j.bbadis.2013.09.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  76 in total

1.  X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily.

Authors:  V Dhanaraj; Q Z Ye; L L Johnson; D J Hupe; D F Ortwine; J B Dunbar; J R Rubin; A Pavlovsky; C Humblet; T L Blundell
Journal:  Structure       Date:  1996-04-15       Impact factor: 5.006

2.  The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells.

Authors:  H Qin; Y Sun; E N Benveniste
Journal:  J Biol Chem       Date:  1999-10-08       Impact factor: 5.157

3.  X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity.

Authors:  A G Pavlovsky; M G Williams; Q Z Ye; D F Ortwine; C F Purchase; A D White; V Dhanaraj; B D Roth; L L Johnson; D Hupe; C Humblet; T L Blundell
Journal:  Protein Sci       Date:  1999-07       Impact factor: 6.725

Review 4.  Proteinases and myocardial extracellular matrix turnover.

Authors:  S C Tyagi
Journal:  Mol Cell Biochem       Date:  1997-03       Impact factor: 3.396

5.  Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity.

Authors:  P C Brooks; S Silletti; T L von Schalscha; M Friedlander; D A Cheresh
Journal:  Cell       Date:  1998-02-06       Impact factor: 41.582

6.  Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease.

Authors:  B Schumacher; P Pecher; B U von Specht; T Stegmann
Journal:  Circulation       Date:  1998-02-24       Impact factor: 29.690

Review 7.  Data-based approach for developing a physical activity frequency questionnaire.

Authors:  M Bernstein; D Sloutskis; S Kumanyika; A Sparti; Y Schutz; A Morabia
Journal:  Am J Epidemiol       Date:  1998-01-15       Impact factor: 4.897

8.  Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.

Authors:  T K Rosengart; L Y Lee; S R Patel; P D Kligfield; P M Okin; N R Hackett; O W Isom; R G Crystal
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

Review 9.  Complex role of matrix metalloproteinases in angiogenesis.

Authors:  Q X Sang
Journal:  Cell Res       Date:  1998-09       Impact factor: 25.617

10.  Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy.

Authors:  S C Tyagi; S G Kumar; S J Haas; H K Reddy; D J Voelker; M R Hayden; T L Demmy; R A Schmaltz; J J Curtis
Journal:  J Mol Cell Cardiol       Date:  1996-07       Impact factor: 5.000

View more
  27 in total

Review 1.  Decellularized Extracellular Matrix Materials for Cardiac Repair and Regeneration.

Authors:  Donald Bejleri; Michael E Davis
Journal:  Adv Healthc Mater       Date:  2019-02-04       Impact factor: 9.933

Review 2.  Decellularized matrices for cardiovascular tissue engineering.

Authors:  Francesco Moroni; Teodelinda Mirabella
Journal:  Am J Stem Cells       Date:  2014-03-13

3.  Docosahexaenoic acid reverses angiotensin II-induced RECK suppression and cardiac fibroblast migration.

Authors:  Jalahalli M Siddesha; Anthony J Valente; Tadashi Yoshida; Siva S V P Sakamuri; Patrice Delafontaine; Hideo Iba; Makoto Noda; Bysani Chandrasekar
Journal:  Cell Signal       Date:  2014-01-19       Impact factor: 4.315

4.  Adiponectin protects rat heart from left ventricular remodeling induced by chronic intermittent hypoxia via inhibition of TGF-β/smad2/3 pathway.

Authors:  Wen-Xiao Ding; Yan-Bin Dong; Ning Ding; Xiao-Feng Zhang; Shi-Jiang Zhang; Xi-Long Zhang; Jian-Nan Liu; Gan Lu
Journal:  J Thorac Dis       Date:  2014-09       Impact factor: 2.895

5.  Reversal of Phospholamban Inhibition of the Sarco(endo)plasmic Reticulum Ca2+-ATPase (SERCA) Using Short, Protein-interacting RNAs and Oligonucleotide Analogs.

Authors:  Kailey J Soller; Jing Yang; Gianluigi Veglia; Michael T Bowser
Journal:  J Biol Chem       Date:  2016-08-16       Impact factor: 5.157

Review 6.  Stem Cell-Derived Exosomes, Autophagy, Extracellular Matrix Turnover, and miRNAs in Cardiac Regeneration during Stem Cell Therapy.

Authors:  Priyanka Prathipati; Shyam Sundar Nandi; Paras Kumar Mishra
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

7.  Targeting miRNA for Therapy of Juvenile and Adult Diabetic Cardiomyopathy.

Authors:  Shyam Sundar Nandi; Paras Kumar Mishra
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

8.  TFAM overexpression reduces pathological cardiac remodeling.

Authors:  George H Kunkel; Christopher J Kunkel; Hazel Ozuna; Irina Miralda; Suresh C Tyagi
Journal:  Mol Cell Biochem       Date:  2018-10-23       Impact factor: 3.396

9.  Pressure overload induces IL-18 and IL-18R expression, but markedly suppresses IL-18BP expression in a rabbit model. IL-18 potentiates TNF-α-induced cardiomyocyte death.

Authors:  Tadashi Yoshida; Ingeborg Friehs; Srinivas Mummidi; Pedro J del Nido; Solange Addulnour-Nakhoul; Patrice Delafontaine; Anthony J Valente; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2014-08-07       Impact factor: 5.000

Review 10.  Gestational Hypoxia and Developmental Plasticity.

Authors:  Charles A Ducsay; Ravi Goyal; William J Pearce; Sean Wilson; Xiang-Qun Hu; Lubo Zhang
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.